{"id":"analogous-gnrh-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Decreased libido"},{"rate":null,"effect":"Erectile dysfunction"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4303227","moleculeType":"Small molecule","molecularWeight":"951.21"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"GnRH antagonists directly bind to and inhibit GnRH receptors on pituitary gonadotroph cells, preventing the release of LH and FSH without an initial flare effect (unlike GnRH agonists). This leads to rapid suppression of testosterone in males and estrogen in females, making them useful for hormone-dependent conditions. The antagonist mechanism provides faster onset of action and avoids the transient hormone surge seen with agonists.","oneSentence":"This GnRH antagonist blocks gonadotropin-releasing hormone receptors to suppress luteinizing hormone and follicle-stimulating hormone, reducing sex hormone production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:09:18.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer (hormone-sensitive)"},{"name":"Hormone-dependent breast cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"}]},"trialDetails":[{"nctId":"NCT01112358","phase":"PHASE2","title":"Lutropin Alfa in Women at Risk of Poor Response","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-12-07","conditions":"Ovarian Stimulation","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":980,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cetrotide®"],"phase":"phase_2","status":"active","brandName":"Analogous GnRH antagonist","genericName":"Analogous GnRH antagonist","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This GnRH antagonist blocks gonadotropin-releasing hormone receptors to suppress luteinizing hormone and follicle-stimulating hormone, reducing sex hormone production. Used for Advanced prostate cancer (hormone-sensitive), Hormone-dependent breast cancer, Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}